In particular, inhibition of CSF1R (by the small-molecule BLZ945 treatment) in TAMs has been a promising intervention for glioblastoma (GBM) in mice; however, persistent usage of CSF1R inhibition can lead to drug resistance in mice [1]. The gene discussed is CSF1R; the disease is glioblastoma.